Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 57

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 16
Chunk 57
---
): 

        Year Ended December 31,

        2024

        2023

        2022

        Balance at beginning of year
         
        $
        2,634

        $
        2,535

        $
        1,141

        Additions based on tax positions related to prior year

        1,433

        29

        726

        Additions based on tax positions related to current year

        2,305

        872

        916

        Reductions based on tax positions related to prior year

        —

        (802
        )

        (248
        )

        Reductions based on tax positions related to current year

        —

        —

        —

        Balance at end of year
         
        $
        6,372

        $
        2,634

        $
        2,535

      The entire amount of the unrecognized tax benefits would not impact the Company’s effective tax rate if recognized. The Company has elected to include interest and penalties as a component of tax expense. During the years ended December 31, 2024, 2023 and 2022, the Company did not recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease during the next 12 months.The Company files income tax returns in the U.S. federal, California and other state tax jurisdictions. The federal and state income tax returns from December 31, 2018 to December 31, 2023 remain subject to examination.

12. Defined Contribution PlanThe Company maintains an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code. All employees are eligible to participate provided that they meet the requirements of the plan. For the year ended December 31, 2024, 2023, and 2022, the Company made matching contributions of $1.7 million, $1.3 million, and $0.8 million, respectively.

13. Segment ReportingThe Company views its operations and manages its business in one operating and one reportable segment, which includes all activities related to the identification, development and commercialization of medicines for childhood and adult diseases with equal intensity. The determination of a single operating segment is consistent with the consolidated financial information regularly provided to the Company’s chief operating decision maker, or 

F-35

CODM. The Company’s CODM is its Chief Executive Officer, who